Status:
COMPLETED
Trial of Sertraline to Treat Children With Fragile X Syndrome
Lead Sponsor:
Randi J. Hagerman, MD
Conditions:
Fragile X Syndrome
Eligibility:
All Genders
24-68 years
Phase:
PHASE2
Brief Summary
This study is a control trial of sertraline (Zoloft) in fragile X syndrome children aged 2 years to 5 years 8 months old. The trial is six months long, and each participant will receive a series of te...
Detailed Description
This is a single center study and the UC Davis MIND Institute for fragile X syndrome (FXS) patients aged between 2 years and 5 years, 8 months old funded by the Health Resources and Services Administr...
Eligibility Criteria
Inclusion
- Fragile X Syndrome
Exclusion
- Current or past SSRI treatment
- Current or past MAOI (monoamine oxidase inhibitor ) treatment
- Serious co-morbid medical disorder affecting brain function and behavior (not including fragile X syndrome).
- Uncontrolled seizure disorder or epilepsy
- Bipolar disorder
- Latex allergies
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT01474746
Start Date
January 1 2012
End Date
September 1 2015
Last Update
September 25 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Davis M.I.N.D. Institute
Sacramento, California, United States, 95817